call antibodi partnership profit
eylea headwind loom
rais estim dupix near-term strong commerci launch
expand label increment sale unlik off-set eylea
dupix headwind beyond solid quarter stronger sale
seen could persist although project headwind begin
eylea novarti brolucizumab approv fda eylea could see sale
soften earli pronounc weak one year
post potenti launch brolucizumab long-term expect continu
competit lead satur anti-vegf market
dupix like near-term driver although sale must flow
sanofi jv notabl regeneron report mab partnership
sanofi profit driven dupix sale cost manag
praluent kevzara note partnership turn profit
regeneron need begin pay sanofi back accru conting
oblig expens reimburs rate regeneron
profit overal think dupix remain strong product
partnership continu uptak three approv indic ad
asthma crswnp result slightli rais dupix forecast base
expand indic atop dermat adolesc crswnp adult
better-than-expect sale trajectori bullish view dupix
partial off-set lower expect praluent given
challeng face regeneron ip litig vs see
note date juli recent german court rule overal
commerci issu product still anticip competitor eylea
long-term lower tp reiter neutral rate
valuat risk valu share use sum-of-the-part sotp
dcf analysi increas ep estim
commerci price market risk
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc engag discoveri
invent develop manufactur commerci
medicin treatment seriou diseas
price aug rate neutral target price analyst evan seigerman
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky scenario assum better expect
sale dupix praluent kevzara libtayo eylea
grey sky scenario assum lower forecast
competit across core busi eylea dupix praluent
libtayo kevzara
long-term see eylea eros brolucizumab biosimilar lucenti
eventu eylea maintain long-term dupix consensu estim
may high despit posit near-term view next year expect
dupix lose share biolog tezepelumab continu
believ long-term consensu dupix expect high account
competit could see develop novel-oncolog pipelin mostli
long-term could counter multipl
compress base-busi remain conserv view regeneron
earli stage pipelin data avail
pipelin updat ophthalmolog franchis eylea approv fda
diabet retinopathi without central involv may regeneron plan
initi higher dose formul includ week regimen aflibercept wet
dme compar current recommend mg everi week
move dupix saw expans label ec approv patient year
older asthma may fda approv adult chronic rhinosinus nasal
polyposi crswnp june ec approv patient year age
moderate-to-sever atop dermat regeneron expect chmp opinion crswnp
addit compani expect submit new data atop dermat
patient age year regul come month libtayo phase
adjuv studi cutan squamou cell carcinoma cscc initi recal
ec grant condit market author libtayo june adult
metastat local advanc cscc surgeri radiat candid
look
bispecif recruit patient r/r follicular lymphoma potenti pivot call
regeneron state phase interim-data copd
atop dermat expect next month compani also state
studi bispecif ovarian cancer r/r multipl
myeloma activ enrol patient preliminari data expect
model adjust increas eylea forecast higher sale
dme dupix rais expect expand label better
expect launch result sanofi collabor addit
cut praluent expect given challeng face regeneron ip litig
lower revenu estim mainli remov fasinumab
mileston payment wait updat regeneron time
revenu increas oper expens tax line updat guidanc
pipelin regeneron announc
figur regeneron quarterli annual ep usd
profit loss tax
cog revenu
 revenu
sg revenu
valuat one-year price target base sum-of-the-part dcf
analysi assum wacc termin growth rate fulli
sotp analysi dcf analysi valu core compon regeneron busi
valu cash flow us sale eylea ou eylea collabor
revenu bayer us sale libtayo regeneron book
split profit partner sanofi valu sanofi collabor
includ antibodi joint-ventur world-wid sale dupix praluent
kevzara addit expens reimburs profit ou libtayo sale
valu valu revenu includ collabor
revenu teva royalti novarti ilari forecast unalloc
corpor expens sg tie specif asset sotp dcf reduc
valuat valu combin net cash result
tp figur
compani mention price
